QTORIN 3.9% Sirolimus Topical Gel
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for QTORIN 3.9% Sirolimus Topical Gel, covering 2024-08-29 to 2024-08-29. Get the full timeline:
Most recent: Clinical Trial Update: CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin Syndrome [Phase 2]